The Changing Face of Multiple Sclerosis: What Are the Experts Looking Forward To?

Slides:

Advertisements

Similar presentations

Applying the New Multiple Sclerosis Guidelines to Clinical Practice

Advertisements

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

New Horizons for SMA.

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

Evolving Paradigms in the Management of HR-Positive Breast Cancer

Highlights From the 2017 Annual European MS Meeting

T-Cell Exhaustion: Can We Overcome It in Cancer?

Challenges in the Diagnosis of MS: Physician and Nurse Perspectives

Progression After Cancer Immunotherapy in Advanced NSCLC

Introduction. Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Endocrine System.

Immune Reconstitution in MS:

What Predicts Disability Progression in Multiple Sclerosis?

Current Controversies in Multiple Sclerosis Management

Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update

Expert Perspectives on Best Practices for Diagnosis and Management of Spinal Muscular Atrophy.

New Standards of Care in ALK-Translocated Advanced NSCLC

What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?

Prolonging Progression-Free Survival in Follicular Lymphoma

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

The Vicious Cycle of Chronic Migraine How Can the Physician Help?

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Optimizing Management of Advanced Bladder Cancer

Updates in Preventing Skeletal-Related Events in Multiple Myeloma

Management Challenges in CLL

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Should I Stay or Should I Go?

Hyperhidrosis Is Burdensome!

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

The JAK-STAT Pathway and Graft-vs-Host Disease

Optimizing Frontline Care for Older Patients With Multiple Myeloma

Treating to Target in MS

How to Select Therapy In Newly Diagnosed CLL

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Nat. Rev. Neurol. doi: /nrneurol

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Expert Perspectives on New Data in Multiple Sclerosis From the 2018 European MS Meeting.

Guide to Atopic Dermatitis

Pediatric Multiple Sclerosis: The Dawn of a New Era?

Clinical Pearls on Hot Topics in MS

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes.

Patient Questions and Expert Answers in Psoriasis:

Evaluating BTK Inhibitors in CLL

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Challenges and Opportunities

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

The Role of Measurable Residual Disease in AML

Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?

Prioritizing Prevention of HPV-Related Disease

Oral Therapies in MS.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Peanut Allergy Immunotherapy

CDK4/6 Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Finding the Right Sequence in Patients With EGFR-Mutated NSCLC

The ABCs of Therapeutic Strategies in Pregnancy and Multiple Sclerosis

Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice.

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a.

Immune Checkpoint Inhibitors in Lung Cancer

Comparative Studies of Biologics in Ulcerative Colitis

A New Era in Migraine Prevention

Presentation transcript:

The Changing Face of Multiple Sclerosis: What Are the Experts Looking Forward To?

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Introduction

MRI and MS

Dissemination Space and Time in CIS 2017 McDonald Criteria

MRI Rationale for Practical Guidelines

Brain Atrophy

MAGNIMS Recommendations

Normative Values for Rate of Brain Volume Changes Over the Lifespan: MAGNIMS

MS Pathophsyiology

MS Pathophsyiology T and B Cells

Imbalances Regulatory Network

Architecture of the Immune System

What Is Needed to Deal With Progression in MS? Faculty Perspective

Possible Mechanisms of Neuroprotection and Repair

DMTs in MS

Selecting Therapy in Clinical Practice Faculty Perspective

First European Treatment Guidelines ECTRIMS/EAN

Clinical Practice Goals

NEDA Faculty Opinion

Lifestyle Changes

Progressive MS Faculty Perspective

Precision Medicine in MS? Faculty Opinion

Abbreviations